These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17646899

  • 1. IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis.
    Bu C, Li Z, Zhang C, Gao L, Cai G.
    Clin Rheumatol; 2008 Feb; 27(2):171-8. PubMed ID: 17646899
    [Abstract] [Full Text] [Related]

  • 2. Thrombotic Primary Antiphospholipid Syndrome: the profile of antibody positivity in patients from North India.
    Ahluwalia J, Sreedharanunni S, Kumar N, Masih J, Bose SK, Varma N, Varma S, Singh S.
    Int J Rheum Dis; 2016 Sep; 19(9):903-12. PubMed ID: 25292011
    [Abstract] [Full Text] [Related]

  • 3. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME, Cabiedes J, Reyes E, Cabral AR.
    Rev Invest Clin; 2005 Sep; 57(4):563-71. PubMed ID: 16315641
    [Abstract] [Full Text] [Related]

  • 4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR.
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [Abstract] [Full Text] [Related]

  • 5. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.
    Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeklik A.
    J Rheumatol; 1997 Sep; 24(9):1710-5. PubMed ID: 9292792
    [Abstract] [Full Text] [Related]

  • 6. Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome.
    Parkpian V, Verasertniyom O, Vanichapuntu M, Totemchokchyakarn K, Nantiruj K, Pisitkul P, Angchaisuksiri P, Archararit N, Rachakom B, Ayurachai K, Janwityanujit S.
    Clin Rheumatol; 2007 Oct; 26(10):1663-70. PubMed ID: 17332980
    [Abstract] [Full Text] [Related]

  • 7. Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.
    Bu C, Zhang C, Li Z, Gao L, Xie Z, Cai G.
    Clin Exp Immunol; 2007 Jul; 149(1):31-9. PubMed ID: 17425656
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
    Samarkos M, Davies KA, Gordon C, Loizou S.
    Clin Rheumatol; 2006 Mar; 25(2):199-204. PubMed ID: 16091839
    [Abstract] [Full Text] [Related]

  • 9. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations.
    Samarkos M, Davies KA, Gordon C, Walport MJ, Loizou S.
    Rheumatology (Oxford); 2001 Sep; 40(9):1026-32. PubMed ID: 11561114
    [Abstract] [Full Text] [Related]

  • 10. Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
    Brenner B, Tavori S, Lerner M, Tatarsky I, Lorber M.
    Isr J Med Sci; 1992 Jan; 28(1):9-15. PubMed ID: 1733904
    [Abstract] [Full Text] [Related]

  • 11. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O, Crippa L, Della Valle P, Sabbadini MG, Viganò D'Angelo S, D'Angelo A.
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [Abstract] [Full Text] [Related]

  • 12. β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.
    Arad A, Proulle V, Furie RA, Furie BC, Furie B.
    Blood; 2011 Mar 24; 117(12):3453-9. PubMed ID: 21245481
    [Abstract] [Full Text] [Related]

  • 13. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC.
    J Rheumatol; 1998 Apr 24; 25(4):667-74. PubMed ID: 9558167
    [Abstract] [Full Text] [Related]

  • 14. Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study.
    Zamora-Medina MDC, Hinojosa-Azaola A, Nuñez-Alvarez CA, Vargas-Ruiz AG, Romero-Diaz J.
    Clin Rheumatol; 2019 Mar 24; 38(3):885-893. PubMed ID: 30515663
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG.
    Thromb Haemost; 1996 Dec 24; 76(6):916-24. PubMed ID: 8972011
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.